

## INTRODUCTION

- Pharmacokinetic small molecules Oxotremorine M (Oxo-M) and PPBP maleate (4-PPBP) induce differentiation of CD146<sup>+</sup> stem/progenitor cells extracted from tendon and periodontal ligament (PDL) tissue.
- We have recently shown that Oxo-M acts via acetylcholine receptor signaling.
- 4-PPBP signaling mechanism remains unknown, despite the potential role of the sigma-1 receptor ( $\sigma$ 1R) in other types of cells.
- This study sought to confirm 4-PPBP as a  $\sigma$ 1R agonist and to identify the intracellular signaling molecules that elicit tendon and PDL regeneration following 4-PPBP treatment





Fig 1. Action of Oxo-M/4-PPBP.

### Hypothesized mechanism of action for 4-PPBP and BD1047




**Fig 2.** Intracellular  $\sigma$ 1R colocalizes with IP3 receptor at the at the mitochondrion-associated endoplasmic reticulum membrane (MAM). We propose that a plasma membrane-localized form of  $\sigma$ 1R initiates second messenger signaling to activate the intracellular  $\sigma$ 1R and induce its translocation from the MAM to the plasma membrane. Subsequent interaction between  $\sigma$ 1R and Src results in ERK1/2 activation and transcription of genes associated with fibrogenic differentiation.

## MATERIALS & METHODS

- CD146<sup>+</sup> rat tendon stem cells (rTSC) and CD146<sup>+</sup> human PDL stem cells (hPDLSC), were treated with  $\sigma$ 1R agonist (50  $\mu$ M 4-PPBP), selective  $\sigma$ 1R antagonist (200  $\mu$ M BD1047), and their combinations (**Fig. 3**).
- Following one treatment with 5-hour incubation, activity of signaling proteins p-ERK1/2 and Src were assessed using western blot.
- Following three treatments with 1 week incubation each, Expression of COLI, COLIII, TNC, and VIM genes were assessed using qRT-PCR

Fig. 3. Procedure overview.



## RESULTS

### $\sigma$ 1R antagonist BD1047 attenuates 4-PPBP-induced p-ERK1/2




Fig 4. Western blot for p-ERK1/2 and Src in CD146<sup>+</sup> rTSC and hPDLSC at 5 hours.

### $\sigma$ 1R antagonist inhibits 4-PPBP-induced gene expressions




Fig 5. qRT-PCR revealed that expressions of COL-I, COL-III, TNC, and VIM induced by 4-PPBP were significantly diminished by BD1047 (\*:p<0.0001 compared to control; n=5 each group).

## DISCUSSION & CONCLUSION

- Western blot data suggested that ERK1/2 and Src signaling are involved in the  $\sigma$ 1R-activated intracellular cascade and potentially linked with improved regeneration of tendon and PDL tissue by Oxo-M and 4-PPBP.
- hPDLSC displayed notable difference in sensitivity to antagonist.
- Increased expression of COLI, COLIII, TNC, and VIM genes indicated tenogenic differentiation of CD146<sup>+</sup> rTSC following treatment with 4-PPBP.
- Silenced gene expression in antagonist and combination groups suggested that lower BD1047 concentration and shortened incubation times are necessary in order to accurately assess gene expression following inhibitor treatment.
- In contrast to uniform rat tissue, human tissue donors' genetic variation, age, and medical history may affect cellular activity and protein expression. COVID-19 limited hPDLSC collection; therefore, future studies will include hPDLSC from a variety of donors in order to establish universal patterns.
- Follow-up studies will investigate how Oxo-M and 4-PPBP apply to an additional intracellular signaling pathway. Using inhibitors of signaling molecules, the chronological order of the cascade will be determined.
- Clinical use of Oxo-M/4-PPBP treatment has potential to accelerate healing following tendon injury, dental trauma, orthodontic tooth movement, and advanced periodontal disease.

## ACKNOWLEDGEMENTS

This study was partially supported by a Columbia University College of Dental Medicine Summer Research Fellowship and NIH/NIDCR 1R01DE029321-01A1 to C.H.L..